SCHEMBL4416028

SCHEMBL4416028

CC(C)(C)OC(=O)N1CCC(OCc2noc(-c3cccc(S(C)(=O)=O)c3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 19/20 0.51
CPT2 P23786 1/20 0.47
CPT1A P50416 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552048 0.90 GPR119 (0.54) GPR119
SCHEMBL4419641 0.88 GPR119 (0.54) GPR119
SCHEMBL4421874 0.87 GPR119 (0.53) GPR119
SCHEMBL14640891 0.87 GPR119 (0.53) GPR119
SCHEMBL4418527 0.86 GPR119 (0.58) GPR119
SCHEMBL4423385 0.86 GPR119 (0.54) GPR119
SCHEMBL4427083 0.86 GPR119 (0.61) GPR119
SCHEMBL4412961 0.86 GPR119 (0.48) GPR119
SCHEMBL4424892 0.85 GPR119 (0.51) GPR119
SCHEMBL4552081 0.85 GPR119 (0.55) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885CPT2 1381/4885CPT1A 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.